Penile cancer (PeCa) is a rare disease worldwide, accounting for less than one percent of all malignancies in men. It usually presents as a painless ulcer or lump on the head of the penis. Squamous cell carcinoma represents the most common histological subtype of PeCa, with pathogenesis intimately linked to chronic Human Papilloma Virus (HPV) infection.
Surgery is the cornerstone for the treatment of primary PeCa with potential mutilating outcome depending on the nodal extension of the disease. However, in case of extensive lymph node involvement, multidisciplinary treatment including perioperative chemotherapy and inclusion in clinical trial should be considered. To date, advanced or metastatic disease still have poor prognosis and are a therapeutic challenge with limited options, highlighting the need of new treatments and further investigations. Growing efforts to identify molecular alterations, understand the role of HPV and characterize immune contexture have expanded over the past years, providing further perspectives in prognostication, predictive biomarkers and therapeutic intervention. In this review, we provide an updated overview of current management of PeCa focusing on perioperative strategy. We discuss about new insights of the biology of PeCa and comment future directions in the field.
Cancer treatment reviews. 2020 Aug 07 [Epub ahead of print]
Florent Peyraud, Clément Allenet, Marine Gross-Goupil, Charlotte Domblides, Félix Lefort, Amaury Daste, Mokrane Yacoub, Thibaud Haaser, Ludovic Ferretti, Grégoire Robert, Alain Ravaud
Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: ., Department of Urology, Bordeaux University Hospital, Bordeaux, France. Electronic address: ., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France. Electronic address: ., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: ., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: ., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France. Electronic address: ., Department of Pathology, Bordeaux University, Bordeaux, France. Electronic address: ., Department of Radiotherapy, Bordeaux University Hospital, Bordeaux, France. Electronic address: ., Department of Urology, HIA Robert-Picqué, Villenave d'Ornon, France. Electronic address: ., Department of Urology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: ., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/32799062